391 related articles for article (PubMed ID: 20131994)
1. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
3. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
4. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Suzuki Y; Saito Y; Terao M; Terada M; Morioka T; Tsuda B; Okamura T; Niikura N; Tokuda Y
Tokai J Exp Clin Med; 2010 Dec; 35(4):148-51. PubMed ID: 21319046
[TBL] [Abstract][Full Text] [Related]
6. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib: a competitor or companion to trastuzumab?
Collins D; Hill AD; Young L
Cancer Treat Rev; 2009 Nov; 35(7):574-81. PubMed ID: 19748186
[TBL] [Abstract][Full Text] [Related]
8. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
10. Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y
Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
12. Jumping higher: is it still possible? The ALTTO trial challenge.
Tomasello G; de Azambuja E; Dinh P; Snoj N; Piccart-Gebhart M
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1883-90. PubMed ID: 19046108
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
14. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
16. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
19. [Clinical aspects of trastuzumab treatment in breast cancer].
Grell P; Svoboda M; Fabián P; Petráková K; Vyzula R
Klin Onkol; 2009; 22(1):3-10. PubMed ID: 19534433
[TBL] [Abstract][Full Text] [Related]
20. [Herceptin-based therapy for breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
